NEW YORK–(BUSINESS WIRE)–#creditratingagency–KBRA releases its fourth-quarter 2025 U.S. Bank Compendium, providing the latest view of the U.S. banking industry NEW YORK–(BUSINESS WIRE)–#creditratingagency–KBRA releases its fourth-quarter 2025 U.S. Bank Compendium, providing the latest view of the U.S. banking industry

KBRA Releases Fourth-Quarter 2025 U.S. Bank Compendium

2026/02/13 07:31
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

NEW YORK–(BUSINESS WIRE)–#creditratingagency–KBRA releases its fourth-quarter 2025 U.S. Bank Compendium, providing the latest view of the U.S. banking industry and analysis of 4Q25 results for publicly traded U.S. banks with KBRA ratings.

In this edition, we examine how KBRA-rated banks delivered their strongest profitability since the pandemic, driven primarily by net interest margin (NIM) expansion. Credit performance continued to soften gradually but remained well within historical norms, with modest increases in nonperforming assets (NPA) and charge-offs concentrated in commercial real estate and commercial and industrial (C&I) portfolios, where loss experience has remained manageable. Capital levels remained sound despite higher share repurchases and increased M&A activity. We also discuss how balance sheet strength, improved earnings, and shifting regulatory priorities are driving increased consolidation activity. Finally, we explore intensifying competition from nonbank financial institutions, fintechs, and newly chartered banking entrants heading into 2026.

The Compendium includes 4Q25 summaries on all publicly traded U.S. banks in KBRA’s rated universe, focusing on key performance and credit metrics, along with medians of key ratios. The Compendium also includes the top 10 lowest cost deposit franchises, highest reserves to loans, and largest sequential changes in return on assets, net interest margin (NIM), net charge-offs, and NPA ratios. Further, we provide a detailed supplement of KBRA-rated debt issues—along with rating, amount issued, coupon, and maturity.

Click here to view the report.

Related Publications

  • Fourth-Quarter 2025 U.S. Bank Compendium Bank Debt Worksheet
  • Fourth-Quarter 2025 U.S. Bank Compendium Ratio Spreadsheet

About KBRA

KBRA, one of the major credit rating agencies, is registered in the U.S., EU, and the UK. KBRA is recognized as a Qualified Rating Agency in Taiwan, and is also a Designated Rating Organization for structured finance ratings in Canada. As a full-service credit rating agency, investors can use KBRA ratings for regulatory capital purposes in multiple jurisdictions.

Doc ID: 1013441

Contacts

Marshall Birkey, Senior Director
+1 312-680-4175
marshall.birkey@kbra.com

Anna Jezerski, Associate Director
+1 301-960-7047
anna.jezerski@kbra.com

Hunter Chadwick, Associate
+1 301-960-7042
hunter.chadwick@kbra.com

Bain Rumohr, Managing Director
+1 312-680-4166
bain.rumohr@kbra.com

Brian Ropp, Managing Director
+1 301-969-3244
brian.ropp@kbra.com

Shannon Servaes, Managing Director
+1 301-969-3247
shannon.servaes@kbra.com

Ian Jaffe, Senior Managing Director
+1 646-731-3302
ian.jaffe@kbra.com

Joe Scott, Senior Managing Director
+1 646-731-2438
joe.scott@kbra.com

Business Development Contact

Justin Fuller, Managing Director
+1 312-680-4163
justin.fuller@kbra.com

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09